Quick Summary
AI-generated summary
Key Takeaways
- Hindustan Laboratories filed DRHP with SEBI for an Initial Public Offering (IPO).
- The IPO comprises a fresh issue of equity shares and an offer for sale by a promoter.
- Equity shares are proposed for listing on BSE Limited and NSE, subject to approvals.
- Proceeds from the fresh issue will fund growth initiatives and general corporate purposes.
- Choice Capital Advisors is Lead Manager; MUFG Intime India is Registrar for the IPO.
Hindustan Laboratories Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) in connection with its proposed initial public offering (IPO).
The IPO is proposed to comprise a fresh issue of equity shares by the company along with an offer for sale by a promoter selling shareholder. The equity shares are proposed to be listed on BSE Limited and the National Stock Exchange of India Limited, subject to receipt of requisite approvals.
The company proposes to utilise the proceeds from the fresh issue towards funding growth initiatives and general corporate purposes, as detailed in the DRHP. The issue will be undertaken through the book-building process in accordance with SEBI regulations
Choice Capital Advisors Private Limited is acting as the Book Running Lead Manager to the issue, and MUFG Intime India Private Limited is the Registrar to the Offer
Hindustan Laboratories Limited is a Mumbai-based pharmaceutical company incorporated in 2017. It is engaged in the development, manufacturing, and marketing of pharmaceutical formulations, with a focus on quality, regulatory compliance, and operational efficiency.
The company operates from its manufacturing and corporate facilities in Maharashtra and serves a diversified customer base across domestic markets. Its operations are supported by an experienced management team and established quality control systems, enabling it to cater to evolving requirements within the pharmaceutical sector.
Hindustan Laboratories Limited aims to strengthen its market presence by expanding its product portfolio, enhancing manufacturing capabilities, and pursuing sustainable growth opportunities in line with industry trends and regulatory standards.
